GlaxoSmithKline PLC (LON:GSK) had its stock rating retained as ‘Neutral’ in a report released by analysts at JP Morgan Cazenove.
JP Morgan Cazenove today set a target price of 1667 on the company’s stock. According to the analyst this now indicates there is a potential increase of 0.33% from GlaxoSmithKline PLC’s current price of 1661.5.
Over the last twelve months GlaxoSmithKline PLC’s stock price has increased by 30.44% from 1273.74 to 1661.5.
There are currently 4,861,000,000 shares in issue with a current share value of 1661.5 giving GlaxoSmithKline PLC a market capitalisation of 80.77B GBp .
GlaxoSmithKline PLC (LON:GSK) has a 50 day moving average of 1651.49 and a 200 day moving average of 1567.94. The 52 week high for the share price is 1745.56 while the 52 week low for the stock is 1277.25.
GlaxoSmithKline plc (GSK) is a healthcare company. The Company is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company’s segments include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare. The Pharmaceuticals business develops and makes medicines to treat a range of acute and chronic diseases. The Vaccines business develops, produces and distributes over 1.9 million vaccines every day to people across the world. The Consumer Healthcare business develops and markets products in various categories, such as Wellness, Oral health, Nutrition and Skin health. The Pharmaceuticals Research and Development (R&D) focuses on the discovery and development in various areas of research, which include human immunodeficiency virus (HIV) and infectious diseases, oncology, immuno-inflammation, respiratory and rare diseases.